These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1353110)

  • 1. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
    Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Beschi M; Castellano M; Muiesan G
    J Hum Hypertens; 1992 Feb; 6(1):9-15. PubMed ID: 1349920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of doxazosin therapy on risk of coronary heart disease.
    Hansson L
    Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 10. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
    Monsalve P; Vera O; Pérez Acuña F; Medina O; Ostojich K; López B; Torres N; Lugo de Franco V; Fonseca R
    Am Heart J; 1991 Jan; 121(1 Pt 2):356-61. PubMed ID: 1824661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
    Am J Med; 1989 Aug; 87(2A):1S-66S. PubMed ID: 2569821
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
    Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
    Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    Mazzola C; Guerrasio E
    Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plethysmographic effects of doxazosin in essential hypertensive patients.
    Mozzato MG; Buzzaccarini F; Casolino P; Valle R; Serena L; Rubino N; Casiglia E; Semplicini A; Pessina AC
    J Hypertens Suppl; 1989 Dec; 7(6):S290-1. PubMed ID: 2576669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.